Genetic Solutions > ERA

ERA® Endometrial Receptivity Analysis

Maximize the chances of pregnancy without losing valuable embryos

I'm not a health specialist

Download ERA RCT Oral Presentation ASRM 2019

Overview

ERA®
Reasons
Benefits
Indications

What is the ERA® (Endometrial Receptivity Analysis) test?

ERA® test, developed and patented by Igenomix (PCT/ ES2009/000386), is a test designed to evaluate endometrial receptivity.
ERA® is the first diagnostic test that determines each woman’s unique personalized embryo transfer timing, therefore synchronizing the embryo transfer with the individualized window of implantation.

What is the procedure?

1 – Learning from more than 200,000 women, the highest number of cases in the market

With over 200.000 women worldwide having undergone the test, the ERA predictor algorithm is based on artificial intelligence, allowing for continual refinements, and learning from those women who have successfully had pregnacies following the ERA recommendation.
ERA is the test with the most data published about clinically monitoring patients during pregnancy, enabling us to make a personalised embryo transfer recommendation with the highest accuracy.

2 – ERA is the endometrial receptivity test powered by most scientific background in the market

16 external publications supporting ERA and 6 internal with convincing clinical outcome.
Since it was developed and patented in 2009, both the Igenomix research team and independent clinics have written numerous publications showing the results of carrying out a personalised embryo transfer using the ERA.
The first endometrial receptivity test with UNE-EN ISO 15189 accreditation.

3 – The highest published clinical rates compared to any other test in the market

In the recurrent implantation failure (RIF) population, patients who underwent a personalized embryo transfer (pET) guided by ERA had significantly increased clinical outcomes versus those patients who did not undergo a pET guided by ERA. (Jia et al., 2022).
ERA is the endometrial receptivity test with the highest published clinical rates for patients with RIF. (Jia et al., 2022 vs Ohara et al., 2022)
RIF patients who undergo a pET guided by ERA found to have similar outcomes to those achieved by good prognosis patients. (Liu et al., 2022).

4 – Clinical support all the way. The largest Scientific community by your side

Igenomix maintains the strongest scientific team in the market, consisting of 15 global Scientific Advisors, dedicated endometrial specialists, and in-house clinicians to support you all the way.

5 – The originals and the first to approach endometrial health with a 360 view.

More than 65.000 EndomeTRIO (ERA, EMMA, and ALICE) samples analyzed in 5 years. Combined over 26 publications supporting our endometrial tests.
The endometrium is important: an imbalance in the endometrial flora caused by a low level of Lactobacillus and the presence of some pathogens is linked to worse reproductive results. (Moreno et al, AJOG 2016).
The presence of pathogenic bacteria in the endometrium can cause chronic endometritis, a silent illness suffered by 30% of women with infertility problems.(Cicinelli et al, Reprod Sci 2014).
By carrying out the EMMA and ALICE tests in addition to the ERA, we can discount or solve important causes of implantation failure and recurrent miscarriage based on just one sample of the endometrium.

Why use ERA® test?

ERA maximizes your patient’s chances of pregnancy.
This molecular diagnostic tool uses NGS to analyze the expression level of 248 genes related to the status of endometrial receptivity.
ERA is backed by ERA is backed by 25 publications; 16 from Igenomix and 9 external publications.
Proprietary algorithm based on machine learning that minimizes the need for second biopsy (90% of cases).
Allows clinicians to identify transition phases with 12 hours shifts.

Who should use ERA® Endometrial Receptivity Analysis test?

ERA® test is indicated for patients with recurrent implantation failure.

When is the second endometrial biopsy needed?

90 % of cases don’t need a second biopsy. The second biopsy is only required under two circumstances:

Patients with a “Pre-receptive” result needing 2 more days with progesterone.
Patients with a “Post-receptive” result.

Test limitations

Documentation

ERA® Specialist's documents

Clinical Sheets

Download

Brochure

Download

Publications List

Download

EndomeTRIO Manual

Download

Scientific evidence

Relevant related studies:

*Simón et al., In vitro fertilization with personalized blastocyst transfer versus frozen or fresh blastocyst transfer: a multicenter, randomized clinical trial. Fertility and Sterility, 2019; 112. e56-e57. 10.1016/j.fertnstert.2019.07.273.
** Ruiz-Alonso et al., The endometrial receptivity array for diagnosis and personalized embryo transfer as a treatment for patients with repeated implantation failure. Fertility and Sterility, 2013;100(3):818-24. 10.1016/j.fertnstert.2013.05.004.

A genomic diagnostic tool for human endometrial receptivity based on the transcriptomic signature.

Díaz-Gimeno P, Horcajadas JA, Martínez-Conejero JA, Esteban FJ, Alamá P, Pellicer A, Simón C.

Fertil Steril. 2011 Jan;95(1):50-60, 60.e1-15. doi: 10.1016/j.fertnstert.2010.04.063. Epub 2010 Jul 8.

PMID:20619403

The accuracy and reproducibility of the endometrial receptivity array is superior to histology as a diagnostic method for endometrial receptivity.

Díaz-Gimeno P, Ruiz-Alonso M, Blesa D, Bosch N, Martínez-Conejero JA, Alamá P, Garrido N, Pellicer A, Simón C.

Fertil Steril. 2013 Feb;99(2):508-17. doi: 10.1016/j.fertnstert.2012.09.046. Epub 2012 Oct 23.

PMID:23102856

The endometrial receptivity array for diagnosis and personalized embryo transfer as a treatment for patients with repeated implantation failure.

Ruiz-Alonso M, Blesa D, Díaz-Gimeno P, Gómez E, Fernández-Sánchez M, Carranza F, Carrera J, Vilella F, Pellicer A, Simón C.

Fertil Steril. 2013 Sep;100(3):818-24. doi: 10.1016/j.fertnstert.2013.05.004. Epub 2013 Jun 4.

PMID:23756099

The endometrial receptivity array for diagnosis and personalized embryo transfer as a treatment for patients with repeated implantation failure.

Ruiz-Alonso M, Blesa D, Díaz-Gimeno P, Gómez E, Fernández-Sánchez M, Carranza F, Carrera J, Vilella F, Pellicer A, Simón C.

Fertil Steril. 2013 Sep;100(3):818-24. doi: 10.1016/j.fertnstert.2013.05.004. Epub 2013 Jun 4.

PMID:23756099

What a difference two days make: “personalized” embryo transfer (pET) paradigm: a case report and pilot study.

Ruiz-Alonso M, Galindo N, Pellicer A, Simón C.

Hum Reprod. 2014 Jun;29(6):1244-7. doi: 10.1093/humrep/deu070. Epub 2014 Apr 15.

PMID:24737781

What a difference two days make: “personalized” embryo transfer (pET) paradigm: a case report and pilot study.

Ruiz-Alonso M, Galindo N, Pellicer A, Simón C.

Hum Reprod. 2014 Jun;29(6):1244-7. doi: 10.1093/humrep/deu070. Epub 2014 Apr 15.

PMID:24737781

Timing the window of implantation by nucleolar channel system prevalence matches the accuracy of the endometrial receptivity array.

Nejat EJ, Ruiz-Alonso M, Simón C, Meier UT.

Fertil Steril. 2014 Nov;102(5):1477-81. doi: 10.1016/j.fertnstert.2014.07.1254. Epub 2014 Sep 17.

PMID25241377

Impact of final oocyte maturation using gonadotropin-releasing hormone agonist triggering and different luteal support protocols on endometrial gene expression.

Bermejo A, Cerrillo M, Ruiz-Alonso M, Blesa D, Simón C, Pellicer A, Garcia-Velasco JA.

Fertil Steril. 2014 Jan;101(1):138-146.e3. doi: 10.1016/j.fertnstert.2013.09.033. Epub 2013 Oct 29.

PMID:24182413

Is endometrial receptivity transcriptomics affected in women with endometriosis? A pilot study.

Garcia-Velasco JA, Fassbender A, Ruiz-Alonso M, Blesa D, D’Hooghe T, Simon C.

Reprod Biomed Online. 2015 Nov;31(5):647-54. doi: 10.1016/j.rbmo.2015.07.014. Epub 2015 Aug 11.

PMID:26385059

Intrauterine human chorionic gonadotropin infusion in oocyte donors promotes endometrial synchrony and induction of early decidual markers for stromal survival: a randomized clinical trial.

Strug MR, Su R, Young JE, Dodds WG, Shavell VI, Díaz-Gimeno P, Ruíz-Alonso M, Simón C, Lessey BA, Leach RE, Fazleabas AT.

Hum Reprod. 2016 Jul;31(7):1552-61. doi: 10.1093/humrep/dew080. Epub 2016 Apr 26.

PMID:27122490

Does an increased body mass index affect endometrial gene expression patterns in infertile patients? A functional genomics analysis.

Comstock IA, Diaz-Gimeno P, Cabanillas S, Bellver J, Sebastian-Leon P, Shah M, Schutt A, Valdes CT, Ruiz-Alonso M, Valbuena D, Simon C, Lathi RB.

Fertil Steril. 2017 Mar;107(3):740-748.e2. doi: 10.1016/j.fertnstert.2016.11.009. Epub 2016 Dec 2.

PMID:27919438

Window of implantation transcriptomic stratification reveals different endometrial subsignatures associated with live birth and biochemical pregnancy.

Díaz-Gimeno P, Ruiz-Alonso M, Sebastian-Leon P, Pellicer A, Valbuena D, Simón C.

Fertil Steril. 2017 Oct;108(4):703-710.e3. doi: 10.1016/j.fertnstert.2017.07.007. Epub 2017 Aug 30.

PMID:28863933

Inter-cycle consistency versus test compliance in endometrial receptivity analysis test.

Stankewicz T, Valbuena D, Ruiz-Alonso M.

J Assist Reprod Genet. 2018 May 26. doi: 10.1007/s10815-018-1212-7

Effect of mifepristone on the transcriptomic signature of endometrial receptivity.

von Grothusen C, Lalitkumar PG, Ruiz-Alonso M, Boggavarapu NR, Navarro R, Miravet-Valenciano J, Gemzell-Danielsson K, Simon C.

Hum Reprod. 2018 Aug 22. doi: 10.1093/humrep/dey272. [Epub ahead of print] PMID: 30137464

Live birth after embryo transfer in an unresponsive thin endometrium.

Cruz, J. Bellver.

Gynecol Endocrinol. 2014 Jul;30(7):481-4. doi: 10.3109/09513590.2014.900747. Epub 2014 Mar 20.

Endometrial receptivity array: Clinical application.

Mahajan N.

J Hum Reprod Sci. 2015 Jul-Sep;8(3):121-9. doi: 10.4103/0974-1208.165153. Review.

PMID:26538853

Efficacy of the endometrial receptivity array for repeated implantation failure in Japan: A retrospective, two-centers study.

Hashimoto T, Koizumi M, Doshida M, Toya M, Sagara E, Oka N, Nakajo Y, Aono N, Igarashi H, Kyono K.

Reprod Med Biol. 2017 Jun 27;16(3):290-296. doi: 10.1002/rmb2.12041. eCollection 2017 Jul.

PMID:29259480

The role of the endometrial receptivity array (ERA) in patients who have failed euploid embryo transfers.

Tan J, Kan A, Hitkari J, Taylor B, Tallon N, Warraich G, Yuzpe A, Nakhuda G.

J Assist Reprod Genet. 2018 Jan 11. doi: 10.1007/s10815-017-1112-2.

PMID:29327111

The Reproductive Outcomes for the Infertile Patients with Recurrent Implantation Failures May Be Improved by Endometrial Receptivity Array Test.

Ota, T., Funabiki, M., Tada, Y., Karita, M., Hayashi, T., Maeda, K. et al.

Journal of Medical Cases. 2019; 10(5), 138-140. doi: https://doi.org/10.14740/jmc3282

Why results of endometrial receptivity assay testing should not be discounted in recurrent implantation failure?
Simrandeep K., Padmaja N. The Onco Fertility Journal. 2019; 2(1): 46-49.

Personalized Embryo Transfer Helps in Improving In vitro Fertilization/ICSI Outcomes in Patients with Recurrent Implantation Failure.

Patel JA, Patel AJ, Banker JM, Shah SI, Banker MR. J Hum Reprod Sci. 2019; 12(1):59-66. doi: 10.4103/jhrs.JHRS_74_18.

Endometrial Receptivity Analysis – a tool to increase an implantation rate in assisted reproduction.

Hromadová L; Tokareva I; Veselá K; Trávník P; Veselý J. Ceska Gynekol. 2019; 84(3): 177-183.

Correlation between plasmatic progesterone, endometrial receptivity genetic assay and implantation rates in frozen-thawed transferred euploid embryos. A multivariate analysis.

Barrenetxea G, Romero I, Celis R, Abio A, Bilbao M, Barrenetxea J. Eur J Obstet Gynecol Reprod Biol. 2021 Aug;263:192-197.

Igenomix and fertility

We work to make a world in which infertility is no longer an impossible barrier. Together with clinics and fertility doctors worldwide we investigate human reproduction to change the lives of couples who are trying to conceive.

Other services

EndomeTRIO

A new dimension of endometrial health to improve your reproductive prognosis More information

EMMA

Evaluates the endometrium at the microbiological level

More information

ALICE

Detects the bacteria causing chronic endometritis

More information

Igenomix is in the media

Igenomix is not affiliated with any news outlet or publication identified above. News coverage does not constitute an endorsement of Igenomix or its products.

Are you interested?

Overview

What is the ERA® (Endometrial Receptivity Analysis) test?

What is the procedure?

1 – Learning from more than 200,000 women, the highest number of cases in the market

2 – ERA is the endometrial receptivity test powered by most scientific background in the market

3 – The highest published clinical rates compared to any other test in the market

4 – Clinical support all the way. The largest Scientific community by your side

5 – The originals and the first to approach endometrial health with a 360 view.

Why use ERA® test?

Who should use ERA® Endometrial Receptivity Analysis test?

When is the second endometrial biopsy needed?

Test limitations

Documentation

Clinical Sheets

Brochure

Publications List

EndomeTRIO Manual

Scientific evidence

Relevant related studies:

Relevant studies:

Can we help you?

Igenomix and fertility

EndomeTRIO

EMMA

ALICE